Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

12 Jan 2022

Scientists describe dynamic genomic landscape of tumor heterogeneity in hepatocellular carcinoma

Clinician scientists and scientists from the National Cancer Centre Singapore and A*STAR's Genome Institute of Singapore, in collaboration with Singapore General Hospital, the National University Health System, Duke-NUS Medical School, Nanyang Technological University, and collaborators from China, Malaysia, Thailand and the Philippines, have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma (HCC).

13 Dec 2021

CRISPR/Cas9 gene editing enables sonodynamic therapy to effectively shrink tumors

Sonodynamic therapy uses ultrasound in combination with drugs to release harmful reactive oxygen species (ROS) at the site of a tumor.

8 Dec 2021

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

25 Nov 2021

New score developed to predict outcome in liver cancer patients receiving immunotherapy

There are still no established biomarkers to predict the success of immunotherapy in patients with liver cancer.

22 Nov 2021

Oncologists use immunotherapy at faster rates for trial-ineligible patients, study finds

Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

9 Nov 2021

Targeting Shp2 in oncological treatments appears to worsen the disease

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.

9 Nov 2021

Exosomal and non-exosomal miRNAs may serve as biomarkers for HCV-related cirrhosis, liver cancer

Oncotarget published "Exosomal and non-exosomal miRNA expression levels in patients with HCV-related cirrhosis and liver cancer" which reported that patients with HCV-related cirrhosis are at risk for liver cancer development.

11 Oct 2021

CXCR6/CXCL16 axis has significant role in the immuno-pathogenesis of severe COVID-19

In a study published on the preprint server medRxiv*, scientists studying the SARS-CoV-2 genome have identified a region linked with the disease severity.

16 Sep 2021

Prognostic impact of common type of liver cancer depends on tumor size, research reveals

Researchers at the Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine have shown that the prognostic impact of hepatocellular carcinoma (HCC), the most common type of liver cancer, is dependent on tumor size.

6 Sep 2021

Study identifies a novel potential biomarker for hepatocellular carcinoma

Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.

23 Aug 2021

Magnetic nanoparticles could enhance the efficacy of cancer immunotherapy

Boosting the function of natural killer cells with magnetic nanoparticles could make cancer immunotherapy more efficient.

6 Aug 2021

Scientists identify new therapeutic target for several aggressive cancers

A protein in tumor cells could be targeted to treat some types of aggressive cancer including brain, blood, skin, and kidney, new research has shown.

4 Aug 2021

Study shows safety and efficacy of radio-wave therapy for liver cancer patients

Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.

30 Jul 2021

Drug combination could make curative surgery possible for some liver cancer patients

A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.

29 Jul 2021

Two new proteins identified as therapeutic targets for preventing NAFLD and associated liver cancer

An international study led by the Lipids&Liver research team at the UPV/EHU-University of the Basque Country, the results of which have recently been published in the prestigious journal Cancer Research, has demonstrated that inhibiting either of the proteins E2F1 or E2F2 in the liver protects against the development of obesity-driven nonalcoholic fatty liver disease and its progression to cancer.

29 Jul 2021

New insights can guide precise personalized hepatocellular carcinoma medicine

A research group led by Prof. PIAO Hailong from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) identified hepatocellular carcinoma (HCC) subtypes with distinctive metabolic phenotypes through bioinformatics and machine learning methods, and elucidated the potential mechanisms based on a metabolite-protein interaction network and multi-omics data.

12 Jul 2021

A new study reveals unintended CRISPR/Cas9 editing events

A recent study by researchers from Sweden and the United Kingdom shows that CRISPR/Cas9-based genomic engineering can prompt unwanted on-target effects, and highlights the complexity of human DNA repair mechanisms in the presence of the powerful prokaryotic Cas9 nuclease. The paper is currently available on the bioRxiv* preprint server.

4 Jul 2021

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

Oncotarget published "Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib" which reported that this study investigated the association of the IGF/CTP score with overall survival and progression-free survival of HCC patients treated with sorafenib.

28 Jun 2021

Experts call for more programs to help Aboriginal and Torres Strait Islander people with liver cancer

Rising numbers of liver cancer in Aboriginal and Torres Strait Islander communities has led experts at Flinders University to call for more programs, including mobile liver clinics and ultrasound in rural and remote Australia.

15 Jun 2021